Physician profile
Harry Wang
NPI 1801320163
$1,525.50
in general payments reported to CMS, 2019-2025
19 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $178 · 2024: $664 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $310.82 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.25 | 2023-2025 | Jardiance |
| Amgen INC. | $149.36 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $124.79 | 2023-2025 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $112.22 | 2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.06 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $81.20 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $78.38 | 2025 | |
| Philips North America LLC | $48.23 | 2024-2025 | Mcot, (5044) Mcot |
| Pfizer INC. | $44.85 | 2023-2024 | |
| Scpharmaceuticals INC. | $35.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $34.59 | 2023-2024 | Verquvo |
| Atricure, INC. | $31.26 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Novo Nordisk INC | $31.00 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $22.10 | 2023 | Definity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $16.31 | 2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $15.32 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $14.66 | 2025 | Onpattro |
| Cvrx, INC. | $14.36 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.